Dr. Yungpo B. Su, MD

Dr. Su practices at Nebraska Methodist Hospital in Omaha, Nebraska.

Dr. Su's NPI, 1457322166, was assigned on January 30, 2006. Dr. Su graduated from New York University School of Medicine in 1998. Dr. Su holds Nebraska license 23746.

Dr. Su's primary practice is Nebraska Methodist Hospital, at 8303 Dodge St, Omaha, NE 68114 in Douglas County. The practice phone is (402) 354-4000.

Dr. Su's primary practice is Nebraska Methodist Hospital in Omaha, Nebraska. Dr. Su is also affiliated with CHI Health Creighton University Medical Center - Bergan Mercy. The medical group on file is Nebraska Cancer Specialists. Dmand AI also links Dr. Su to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Su practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Su's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Su is licensed in Nebraska.

CMS data shows 148,523 Medicare services from Dr. Su across 49 procedure codes in 2024, for 609 Medicare patients. Medicare paid $2,660,337 for them.

CMS counts 609 Medicare patients who saw Dr. Su in 2024. The largest group is 65 to 74, with 296 patients. 71% of them have high blood pressure, and 70% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Su's median patient age at 67, with 43% women.

In 2024, Dr. Su wrote 1,093 Medicare Part D claims for 174 patients. 84% of them were for generic drugs. CMS names the drug for 956 of them, across 20 drugs with 11 or more claims each, at $12,007 in total drug cost. In 2023, CMS named 670 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Su for performance year 2024, reported as part of a group. Dr. Su accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Su, published from 2012 to 2025. 2015 was the busiest year, with 3. The most frequent topics are Carcinoma, Squamous Cell, Antineoplastic Combined Chemotherapy Protocols and Neoadjuvant Therapy. Dr. Su has published most often in Head Neck. Dr. Su's most frequent co-authors are Nikhil Ishwar Khushalani, MBBS, MD, Jennifer Lynn Atlas, MD and Jennifer H. Choe, MD, PhD.

Dmand AI links Dr. Su to 7 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Lymphoid Interstitial Pneumonia, Nasopharyngeal Carcinoma and Skin Neoplasms. Alliance for Clinical Trials in Oncology sponsors the most, 3.

CMS Open Payments shows 20 general payments to Dr. Su from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 85% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $2,100. It also lists 31 research payments totaling $4,530 from 2022 to 2025.

Dr. Su graduated from New York University School of Medicine in 1998.